Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

OBJECTIVE: Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying acquired resistance are still unknown. Herein, we characterise the role of tumour-initiating cells (T-ICs) and signalling pathways involved in sor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gut
Autors principals: Tovar, Victoria, Cornella, Helena, Moeini, Agrin, Vidal, Samuel, Hoshida, Yujin, Sia, Daniela, Peix, Judit, Cabellos, Laia, Alsinet, Clara, Torrecilla, Sara, Martinez-Quetglas, Iris, Lozano, Juan José, Desbois-Mouthon, Christèle, Solé, Manel, Domingo-Domenech, Josep, Villanueva, Augusto, Llovet, Josep M
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600200/
https://ncbi.nlm.nih.gov/pubmed/26658144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2015-309501
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars